RiverFront Investment Group LLC Acquires 1,232 Shares of McKesson Corporation $MCK

Posted by Brenda Bartman on May 19th, 2026

RiverFront Investment Group LLC lifted its holdings in shares of McKesson Corporation (NYSE:MCK – Free Report) by 315.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,623 shares of the company’s stock after acquiring an additional 1,232 shares during the quarter. RiverFront Investment Group LLC’s holdings in McKesson were worth $1,331,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. J.W. Cole Advisors Inc. raised its stake in McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock worth $3,931,000 after buying an additional 1,329 shares in the last quarter. Cullen Investment Group LTD. raised its stake in McKesson by 550.4% in the fourth quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock worth $3,811,000 after buying an additional 3,952 shares in the last quarter. Private Wealth Partners LLC raised its stake in McKesson by 5.6% in the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after buying an additional 1,682 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in McKesson by 12.4% in the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after purchasing an additional 36,451 shares in the last quarter. Finally, AlphaQuest LLC raised its holdings in McKesson by 91.2% in the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after purchasing an additional 843 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Price Performance

Shares of NYSE:MCK opened at $775.38 on Tuesday. McKesson Corporation has a 1-year low of $637.00 and a 1-year high of $999.00. The business has a fifty day moving average price of $851.72 and a 200-day moving average price of $857.32. The company has a market capitalization of $93.20 billion, a PE ratio of 20.16, a PEG ratio of 1.13 and a beta of 0.35.

McKesson (NYSE:MCK – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, beating the consensus estimate of $11.56 by $0.13. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The firm had revenue of $96.30 billion during the quarter, compared to the consensus estimate of $101.35 billion. During the same period last year, the company earned $10.12 earnings per share. The company’s revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, sell-side analysts anticipate that McKesson Corporation will post 44.29 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, June 1st. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is presently 8.53%.

Insider Buying and Selling at McKesson

In related news, Director Maria Martinez sold 349 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the sale, the director directly owned 301 shares of the company’s stock, valued at $282,900.87. This trade represents a 53.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michele Lau sold 2,725 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares in the company, valued at $3,214,530. This trade represents a 45.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MCK shares. Bank of America decreased their price objective on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a report on Monday, April 6th. Citigroup decreased their price objective on McKesson from $975.00 to $945.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Raymond James Financial set a $970.00 price objective on McKesson in a report on Thursday, March 5th. Wall Street Zen upgraded McKesson from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Barclays increased their price objective on McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $968.87.

Check Out Our Latest Report on MCK

McKesson Company Profile

(Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.